Patents by Inventor Avi Eldar
Avi Eldar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11583579Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.Type: GrantFiled: March 5, 2021Date of Patent: February 21, 2023Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, RAMOT AT TEL-AVIV UNIVERSITY LTD., KIMRON VETERINARY INSTITUTEInventors: W. Ian Lipkin, Thomas Briese, Nischay Mishra, Eran Bacharach, Avi Eldar
-
Publication number: 20210205437Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.Type: ApplicationFiled: March 5, 2021Publication date: July 8, 2021Inventors: W. Ian LIPKIN, Thomas BRIESE, Nischay Mishra, Eran Bacharach, Avi Eldar
-
Patent number: 10973902Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.Type: GrantFiled: February 6, 2020Date of Patent: April 13, 2021Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, RAMOT AT TEL-AVIV UNIVERSITY LTD., KIMRON VETERINARY INSTITUTEInventors: W. Ian Lipkin, Thomas Briese, Nischay Mishra, Eran Bacharach, Avi Eldar
-
Publication number: 20200254084Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.Type: ApplicationFiled: February 6, 2020Publication date: August 13, 2020Inventors: W. Ian LIPKIN, Thomas BRIESE, Nischay Mishra, Eran Bacharach, Avi Eldar
-
Patent number: 10596249Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.Type: GrantFiled: August 23, 2018Date of Patent: March 24, 2020Assignees: KIMRON VETERINARY INSTITUTE, THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK, RAMOT AT TEL-AVIV UNIVERISTY LTD.Inventors: W. Ian Lipkin, Thomas Briese, Nischay Mishra, Eran Bacharach, Avi Eldar
-
Patent number: 10537631Abstract: The present invention relates to vaccine compositions comprising attenuated strain of Tilapia Lake Virus (TiLV) for protecting tilapia fish against infection by (TiLV). The invention also relates to methods for using the vaccines to protect tilapines from TiLV-induced disease.Type: GrantFiled: August 13, 2018Date of Patent: January 21, 2020Assignees: The State of Israel, Ministry of Agriculture & Rural Developement, Kimron Veterinary Institute, Ramot At Tel-Aviv University Ltd.Inventors: Eran Bacharach, Avi Eldar
-
Publication number: 20190216914Abstract: The present invention relates to vaccine compositions comprising attenuated strain of Tilapia Lake Virus (TiLV) for protecting tilapia fish against infection by (TiLV). The invention also relates to methods for using the vaccines to protect tilapines from TiLV-induced disease.Type: ApplicationFiled: August 13, 2018Publication date: July 18, 2019Inventors: Eran Bacharach, Avi Eldar
-
Patent number: 10183072Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.Type: GrantFiled: December 15, 2015Date of Patent: January 22, 2019Assignees: KIMRON VETERINARY INSTITUTE, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: W. Ian Lipkin, Thomas Briese, Nischay Mishra, Eran Bacharach, Avi Eldar
-
Publication number: 20180369360Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.Type: ApplicationFiled: August 23, 2018Publication date: December 27, 2018Inventors: W. Ian Lipkin, Thomas Briese, Nischay Mishra, Eran Bacharach, Avi Eldar
-
Patent number: 10071152Abstract: The present invention relates to vaccine compositions comprising attenuated strain of Tilapia Lake Virus (TiLV) for protecting tilapia fish against infection by (TiLV). The invention also relates to methods for using the vaccines to protect tilapines from TiLV-induced disease.Type: GrantFiled: July 10, 2017Date of Patent: September 11, 2018Assignees: Kimron Veterinary Institute, Ramot at Tel-Avin University Ltd.Inventors: Eran Bacharach, Avi Eldar
-
Publication number: 20180008692Abstract: The present invention relates to vaccine compositions comprising attenuated strain of Tilapia Lake Virus (TiLV) for protecting tilapia fish against infection by (TiLV). The invention also relates to methods for using the vaccines to protect tilapines from TiLV-induced disease.Type: ApplicationFiled: July 10, 2017Publication date: January 11, 2018Inventors: Eran Bacharach, Avi Eldar
-
Publication number: 20170360918Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.Type: ApplicationFiled: December 15, 2015Publication date: December 21, 2017Inventors: W. Ian LIPKIN, Thomas BRIESE, Nischay Mishra, Eran Bacharach, Avi Eldar
-
Patent number: 9730998Abstract: The present invention relates to vaccine compositions comprising attenuated strain of Tilapia Lake Virus (TiLV) for protecting tilapia fish against infection by (TiLV). The invention also relates to methods for using the vaccines to protect tilapines from TiLV-induced disease.Type: GrantFiled: February 11, 2015Date of Patent: August 15, 2017Assignees: The State of Israel, Ministry of Agriculture & Rural Development, Kimron Veterinary Institute, Ramot at Tel-Aviv University Ltd.Inventors: Eran Bacharach, Avi Eldar
-
Publication number: 20160354458Abstract: The present invention relates to vaccine compositions comprising attenuated strain of Tilapia Lake Virus (TiLV) for protecting tilapia fish against infection by (TiLV). The invention also relates to methods for using the vaccines to protect tilapines from TiLV-induced disease.Type: ApplicationFiled: February 11, 2015Publication date: December 8, 2016Applicants: The State of Israel, Ministry of Agriculture & Rur al Development, Kimron Veterinary Institute, Ramot at Tel-Aviv University Ltd.Inventors: Eran Bacharach, Avi Eldar
